Predictors of glyburide failure in the treatment of gestational diabetes

Obstet Gynecol. 2006 Jun;107(6):1303-9. doi: 10.1097/01.AOG.0000218704.28313.36.

Abstract

Objective: Our objective was to identify among women with gestational diabetes mellitus (GDM) the patient characteristics that predict treatment failure with glyburide.

Methods: Historical cohort of 95 GDM women offered glyburide after dietary failure with defined entry criteria.

Results: From November 2000 to May 2005, 118 women had 124 pregnancies and were offered glyburide therapy by the 2 codirectors of our Diabetes Clinic. All but 2 women elected glyburide, and 27 pregnancies were excluded due to criteria defined a priori to the study. A cohort of 95 women with 95 pregnancies were included for analysis. Nineteen percent failed glyburide. Significant predictors of failure were maternal age (34 years compared with 29 years, P = .001), earlier diagnosis of GDM (23 weeks compared with 28 weeks, P = .002), higher gravidity (P = .01) and parity (P = .03), and a higher mean fasting blood glucose (112 compared with 100 mg/dL; P = .045) compared with those successfully treated. After adjustment in the multivariable logistic regression analysis, GDM women diagnosed at a gestational age less than 25 weeks were 8.3 times more likely to fail glyburide compared with those diagnosed after 25 weeks. Maternal and fetal outcomes were favorable with a cesarean delivery rate of 25% and macrosomia rate of 7%.

Conclusion: Glyburide was more likely to fail in women diagnosed earlier in pregnancy, of older age and multiparity, and with higher fasting glucoses, suggesting that earlier glucose intolerance and a reduced capacity to respond to an insulin secretagogue may distinguish this group. The time for glyburide as an alternative treatment has come; however, it should be prescribed after careful consideration of these patient characteristics to minimize the likelihood of failure.

Level of evidence: II-2.

MeSH terms

  • Adult
  • Cesarean Section / statistics & numerical data
  • Diabetes, Gestational / drug therapy*
  • Female
  • Fetal Macrosomia / epidemiology
  • Glyburide / therapeutic use*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Pre-Eclampsia / epidemiology
  • Pregnancy
  • Pregnancy Outcome
  • Retrospective Studies
  • Risk Factors
  • Treatment Failure

Substances

  • Hypoglycemic Agents
  • Glyburide